Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

Blood (2024) 144 (14): 1486–1495.

https://doi.org/10.1182/blood.2023023780

Published: 2024

Includes: Supplemental data

Journal Articles

Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies

Dennis A. Eichenauer, Ina Bühnen, Christian Baues, Carsten Kobe, Helen Kaul, Richard Greil, Alden Moccia, Joseé M. Zijlstra, Bernd Hertenstein, Max S. Topp, Marianne Just, Bastian von Tresckow, Hans-Theodor Eich, Michael Fuchs, Markus Dietlein, Sylvia Hartmann, Andreas Engert, Peter Borchmann

Blood (2023) 142 (6): 553–560.

https://doi.org/10.1182/blood.2023019939

Published: 2023

Journal Articles

Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura

Lucas Kühne, Dennis A. Eichenauer, Paul Knöbl, Linus A. Völker, Jessica Kaufeld, Ralph Wendt, Holger Hägele, Thomas Osterholt, Marcus Bieringer, Veronika Buxhofer-Ausch, Jan Menne, Ulf Schoenermarck, Paul Brinkkoetter

Blood (2021) 138 (Supplement 1): 2087.

https://doi.org/10.1182/blood-2021-151283

Published: 2021

Journal Articles

Impact of Timing and Precision of Histopathological Diagnosis on Outcomes of Patients with Burkitt and High-Grade B-Cell Lymphoma

Jan-Michel Heger, Claus Moritz Graef, Philipp Falderbaum, Philipp Gödel, Hyatt Balke-Want, Florian Simon, Noëlle Sieg, Jan-Hendrik Naendrup, Marie Anne-Catherine Neumann, Sarah Gillessen, Paul J Bröckelmann, Dennis A. Eichenauer, Peter Borchmann, Bastian Von Tresckow

Blood (2021) 138 (Supplement 1): 2531.

https://doi.org/10.1182/blood-2021-145283

Published: 2021

Journal Articles

Treatment of Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Subgroup Analysis of the Randomized German Hodgkin Study Group HD16 Study

Dennis A. Eichenauer, Ina Bühnen, Michael Fuchs, Helen Kaul, Carsten Kobe, Sylvia Hartmann, Christian Baues, Bastian von Tresckow, Peter Borchmann, Andreas Engert

Blood (2021) 138 (Supplement 1): 2439.

https://doi.org/10.1182/blood-2021-145427

Published: 2021

Journal Articles

PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group

Michael Fuchs, Anne Sophie Jacob, Helen Kaul, Carsten Kobe, Thomas Pabst, Richard Greil, Dennis A. Eichenauer, Max Topp, Marianne Just, Bernd Hertenstein, Valdete Schaub, Martin Vogelhuber, Josée M Zijlstra, Annette Plütschow, Christian Baues, Andreas Rosenwald, Markus Dietlein, Peter Borchmann, Andreas Engert

Blood (2021) 138 (Supplement 1): 2438.

https://doi.org/10.1182/blood-2021-152260

Published: 2021

Journal Articles

How I treat nodular lymphocyte-predominant Hodgkin lymphoma

Dennis A. Eichenauer, Andreas Engert

Blood (2020) 136 (26): 2987–2993.

https://doi.org/10.1182/blood.2019004044

Published: 2020

Journal Articles

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Sarah Gillessen, MD, Annette Plütschow, Michael Fuchs, MD, Jana Markova, MD, Richard Greil, MD, Max S. Topp, MD, Julia Meissner, MD, Josée M Zijlstra, MD PhD, Dennis A. Eichenauer, Volker Diehl, MD, Peter Borchmann, MD PhD, Andreas Engert, MD, Bastian von Tresckow, MD

Blood (2019) 134 (Supplement_1): 129.

https://doi.org/10.1182/blood-2019-125249

Published: 2019

Journal Articles

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Bastian von Tresckow, MD, Andreas Hüttmann, MD, Vladan Vucinic, MD, Horst Mueller, PhD, Annette Plütschow, Andreas Viardot, MD, Max S. Topp, Carsten Kobe, MD, Boris Böll, MD, Dennis A. Eichenauer, Stephanie Sasse, MD, Heinz Haverkamp, Michael Fuchs, Andreas Engert, MD, Peter Borchmann, MD

Blood (2018) 132 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2018-99-117291

Published: 2018

Journal Articles

Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group

Dennis A. Eichenauer, Annette Plütschow, Lena Schröder, Michael Fuchs, Boris Böll, Bastian von Tresckow, Volker Diehl, Peter Borchmann, Andreas Engert

Blood (2018) 132 (14): 1519–1525.

https://doi.org/10.1182/blood-2018-02-836437

Published: 2018

Journal Articles

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Blood (2017) 130 (Supplement 1): 737.

https://doi.org/10.1182/blood.V130.Suppl_1.737.737

Published: 2017

Journal Articles

R-CHOP in NLPHL: who should receive it?

Dennis A. Eichenauer, Andreas Engert

Blood (2017) 130 (4): 387–388.

https://doi.org/10.1182/blood-2017-05-786301

Published: 2017

Journal Articles

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Annette Pluetschow, Lena Schroeder, Michael Fuchs, MD, Bastian von Tresckow, MD, Volker Diehl, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2016) 128 (22): 922.

https://doi.org/10.1182/blood.V128.22.922.922

Published: 2016

Journal Articles

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Boris Böll, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Felicitas Hitz, Andrea Kerkhoff, Richard Greil, Bastian von Tresckow, Dennis A. Eichenauer, Carolin Bürkle, Sven Borchmann, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann

Blood (2016) 127 (18): 2189–2192.

https://doi.org/10.1182/blood-2015-11-681064

Published: 2016

Journal Articles

Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group

Dennis A. Eichenauer, MD, Helen Goergen, Annette Pluetschow, Karolin Behringer, MD, Stefanie Kreissl, MD, Paul Bröckelmann, MD, Michael Fuchs, MD, Boris Böll, MD, Bastian von Tresckow, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2015) 126 (23): 2729.

https://doi.org/10.1182/blood.V126.23.2729.2729

Published: 2015

Journal Articles

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Pluetschow, Heinz Haverkamp, Stefanie Kreissl, MD, Michael Fuchs, Martin Soekler, Johannes C. Hellmuth, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, Carsten Kobe, Volker Diehl, MD, Andreas Engert

Blood (2015) 126 (23): 580.

https://doi.org/10.1182/blood.V126.23.580.580

Published: 2015

Journal Articles

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Achim Rothe, Stephanie Sasse, Max S. Topp, Dennis A. Eichenauer, Horst Hummel, Katrin S. Reiners, Markus Dietlein, Georg Kuhnert, Joerg Kessler, Carolin Buerkle, Miroslav Ravic, Stefan Knackmuss, Jens-Peter Marschner, Elke Pogge von Strandmann, Peter Borchmann, Andreas Engert

Blood (2015) 125 (26): 4024–4031.

https://doi.org/10.1182/blood-2014-12-614636

Published: 2015

Journal Articles

Treatment of Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): An Analysis from the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Annette Pluetschow, Michael Fuchs, MD, Karolin Behringer, MD, Boris Böll, MD, Bastian von Tresckow, MD, Volker Diehl, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2014) 124 (21): 3058.

https://doi.org/10.1182/blood.V124.21.3058.3058

Published: 2014

Journal Articles

Doxorubicin, Vinblastine and Dacarbazine with or without Bleomycin for Older Patients with Early Stage Favorable Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 Trials

Boris Böll, MD, Karolin Behringer, MD, Helen Görgen, Paul Bröckelmann, MD, Bastian von Tresckow, MD, Dennis A. Eichenauer, MD, Michael Fuchs, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2014) 124 (21): 3062.

https://doi.org/10.1182/blood.V124.21.3062.3062

Published: 2014

Journal Articles

A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Bastian von Tresckow, MD, Annette Pluetschow, Heinz Haverkamp, Vladan Vucinic, MD, Andreas Rank, MD, Max S. Topp, MD, Michaela Feuring-Buske, MD, Carsten Kobe, MD, Georg Kuhnert, MD, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Michael Fuchs, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2014) 124 (21): 4433.

https://doi.org/10.1182/blood.V124.21.4433.4433

Published: 2014

NARROW

Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies

Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura

Impact of Timing and Precision of Histopathological Diagnosis on Outcomes of Patients with Burkitt and High-Grade B-Cell Lymphoma

Treatment of Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Subgroup Analysis of the Randomized German Hodgkin Study Group HD16 Study

PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group

How I treat nodular lymphocyte-predominant Hodgkin lymphoma

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

R-CHOP in NLPHL: who should receive it?

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group (GHSG)

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Treatment of Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): An Analysis from the German Hodgkin Study Group (GHSG)

Doxorubicin, Vinblastine and Dacarbazine with or without Bleomycin for Older Patients with Early Stage Favorable Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 Trials

A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only